CLINICAL_TRIALS
trial_result
· 2013-02-22
Clinical Trial Update: Safety, Tolerability and Efficacy of Microsomal Triglyceride Protein (MTP) Inhibitor [Phase 2]
Summary
Phase 2 results update on lomitapide, a microsomal triglyceride transfer protein inhibitor, evaluating safety, tolerability and efficacy in homozygous familial …
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Aegerion Pharmaceuticals, Inc. | Conditions: Homozygous Familial Hypercholesterolemia | Phase 2 | Status: COMPLETED | Results posted: 2013-02-22